
Prothena (PRTA) Stock Forecast & Price Target
Prothena (PRTA) Analyst Ratings
Bulls say
Prothena Corp has demonstrated encouraging clinical results in reducing amyloid levels for its investigational therapies, particularly at the 200mg and 400mg dose levels, which is significant for the treatment of neurodegenerative diseases. The company has projected potential earnings of up to $105 million, approximately $2 per basic share outstanding, from development milestones related to its partnerships with Novo Nordisk and Bristol-Myers Squibb by 2026. Additionally, despite some concerns regarding elevated ARIA incidence in one of its treatments, PRX012 has shown overall favorable tolerability with low incidence of injection-site reactions, reinforcing a generally positive outlook on the company’s development pipeline.
Bears say
Prothena Corp PLC faces a negative outlook due to its continued net losses, which are expected to persist until product approval or commercialization, indicating significant financial strain in the near term. The company may need to raise additional capital to support the development of its drug candidates, which poses a risk of dilution to existing shareholders and adds uncertainty regarding future shareholder value. Moreover, potential changes in regulatory stances could introduce obstacles to product approvals, further complicating the company's financial position and its ability to generate revenue.
This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.
Prothena (PRTA) Analyst Forecast & Price Prediction
Start investing in Prothena (PRTA)
Order type
Buy in
Order amount
Est. shares
0 shares